Related Experiment Video
Updated: Sep 21, 2026

Modeling Neonatal Intraventricular Hemorrhage Through Intraventricular Injection of Hemoglobin
Published on: August 25, 2022
[High-dose intravenous immunoglobulin therapy in a child case of Bickerstaff's brainstem encephalitis]
Nobuyoshi Sugiyama1, Shin-ichiro Hamano, Michiaki Koga
1Division of Neurology, Saitama Children's Medical Center, Iwatsuki, Saitama. nobuyosi@is.icc.u-tokai.ac.jp
Insights
Bickerstaff
Area of Science:
- Neurology
- Immunology
Background:
- Bickerstaff's brainstem encephalitis (BBE) is a rare neurological disorder.
- Its exact pathophysiology and optimal treatment remain unclear.
Observation:
- An 11-year-old boy presented with BBE following an upper respiratory infection.
- Symptoms included gait disturbance, consciousness impairment, diplopia, cranial nerve palsy, limb weakness, cerebellar ataxia, and areflexia.
- Cerebrospinal fluid showed albuminocytologic dissociation, and serum revealed IgG antibodies against GQ1b and GT1a.
Findings:
- Intravenous immunoglobulin (IVIG) therapy initiated on day 11 led to gradual symptom improvement.
- The patient recovered significantly by discharge, with residual mild ophthalmoparesis and areflexia resolving within 10 months.
- The case exhibited features overlapping with Guillain-Barré syndrome (GBS) and Miller Fisher syndrome.
Implications:
- BBE and GBS appear closely related, sharing clinical and immunological characteristics.
- IVIG, a standard treatment for GBS, should be considered for managing BBE.
- This case highlights the potential efficacy of IVIG in BBE treatment.
Abstract:
We report an 11-year-old boy with Bickerstaff's brainstem encephalitis (BBE). He had gait disturbance, disturbed consciousness, and diplopia after upper respiratory tract infection. On admission, he showed multiple cranial nerve palsy, muscle weakness of arms, cerebeller ataxia and generalized areflexia. The cerebrospinal fluid on day 7 revealed albuminocytologic dissociation. IgG antibodies against GQ1b and GT1a were detected in the serum. Immunoglobulin was administered intravenously from day 11, and then his symptoms gradually diminished. When he was discharged on day 27, he had neither conscious disturbance nor limb weakness. There still were mild ophthalmoparesis and diminished deep tendon reflexes, but they disappeared by 10 months after the onset. Effective therapy for BBE has yet to be established. Our case had features of Guillain-Barré syndrome (GBS) and Miller Fisher syndrome, such as an acute monophasic course, limb weakness with areflexia, albuminocytologic dissociation in the cerebrospinal fluid, detection of serum anti-ganglioside antibodies and efficacy of intravenous immunoglobulin, indicating that BBE and GBS are closely related. Our case suggested that intravenous immunoglobulin therapy, an established treatment for GBS, should be considered in some patients with BBE.
Related Concept Videos
Encephalitis l: Introduction
Encephalitis ll: Pathophysiology
Rocky Mountain Spotted Fever
Diphtheria
